ES2769607T3 - Derivados de prolina sulfonamida como antagonistas del receptor de orexina - Google Patents
Derivados de prolina sulfonamida como antagonistas del receptor de orexina Download PDFInfo
- Publication number
- ES2769607T3 ES2769607T3 ES11758563T ES11758563T ES2769607T3 ES 2769607 T3 ES2769607 T3 ES 2769607T3 ES 11758563 T ES11758563 T ES 11758563T ES 11758563 T ES11758563 T ES 11758563T ES 2769607 T3 ES2769607 T3 ES 2769607T3
- Authority
- ES
- Spain
- Prior art keywords
- disorder
- disorders
- phenyl
- compound
- orexin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Proline sulfonamide Chemical class 0.000 title description 53
- 229940123730 Orexin receptor antagonist Drugs 0.000 title description 13
- 229940124530 sulfonamide Drugs 0.000 title description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 121
- 239000003814 drug Substances 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- MKARNSWMMBGSHX-UHFFFAOYSA-N 3,5-dimethylaniline Chemical compound CC1=CC(C)=CC(N)=C1 MKARNSWMMBGSHX-UHFFFAOYSA-N 0.000 claims abstract description 11
- LWZATQDWEXAGQR-NSHDSACASA-N (2s)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(O)=O)CCC1 LWZATQDWEXAGQR-NSHDSACASA-N 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 86
- 208000035475 disorder Diseases 0.000 claims description 51
- 208000019901 Anxiety disease Diseases 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 35
- 208000019116 sleep disease Diseases 0.000 claims description 32
- 230000035882 stress Effects 0.000 claims description 31
- 206010012335 Dependence Diseases 0.000 claims description 30
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 22
- 206010022437 insomnia Diseases 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 18
- 208000010877 cognitive disease Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000019022 Mood disease Diseases 0.000 claims description 15
- 208000020016 psychiatric disease Diseases 0.000 claims description 14
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 13
- 208000027559 Appetite disease Diseases 0.000 claims description 10
- 208000020685 sleep-wake disease Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010034912 Phobia Diseases 0.000 claims description 2
- 208000000810 Separation Anxiety Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 230000003938 response to stress Effects 0.000 claims description 2
- 208000025874 separation anxiety disease Diseases 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 description 89
- 108060005714 orexin Proteins 0.000 description 88
- 241000700159 Rattus Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 230000015654 memory Effects 0.000 description 19
- 230000007958 sleep Effects 0.000 description 19
- 206010070834 Sensitisation Diseases 0.000 description 18
- 230000008313 sensitization Effects 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000003542 behavioural effect Effects 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 229960005181 morphine Drugs 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 230000037007 arousal Effects 0.000 description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 206010062519 Poor quality sleep Diseases 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 230000003137 locomotive effect Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 102000008834 Orexin receptor Human genes 0.000 description 9
- 235000014632 disordered eating Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 229960002429 proline Drugs 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000030814 Eating disease Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000013016 learning Effects 0.000 description 8
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 8
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 7
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 108050000742 Orexin Receptor Proteins 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 229960003920 cocaine Drugs 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 230000037053 non-rapid eye movement Effects 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 208000011117 substance-related disease Diseases 0.000 description 7
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 6
- DKMACHNQISHMDN-RPLLCQBOSA-N Almorexant Chemical compound C([C@H]1C2=CC(OC)=C(OC)C=C2CCN1[C@@H](C(=O)NC)C=1C=CC=CC=1)CC1=CC=C(C(F)(F)F)C=C1 DKMACHNQISHMDN-RPLLCQBOSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 6
- 206010026749 Mania Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 230000001143 conditioned effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 208000024714 major depressive disease Diseases 0.000 description 6
- 229960002715 nicotine Drugs 0.000 description 6
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 6
- OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 201000009032 substance abuse Diseases 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
- 206010020843 Hyperthermia Diseases 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 208000001871 Tachycardia Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 206010013663 drug dependence Diseases 0.000 description 5
- 238000000537 electroencephalography Methods 0.000 description 5
- 238000002567 electromyography Methods 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 230000036031 hyperthermia Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000007787 long-term memory Effects 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000004037 social stress Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 230000006794 tachycardia Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- NHPQGZOBHSVTAQ-IBGZPJMESA-N (2s)-n-(3,5-dimethylphenyl)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(C)C=C(C)C=2)CCC1 NHPQGZOBHSVTAQ-IBGZPJMESA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
- 206010006550 Bulimia nervosa Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 108090000189 Neuropeptides Proteins 0.000 description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 208000005793 Restless legs syndrome Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229940025084 amphetamine Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000019439 energy homeostasis Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000029364 generalized anxiety disease Diseases 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940127240 opiate Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000003797 Neuropeptides Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010033664 Panic attack Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003935 attention Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002060 circadian Effects 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 230000004461 rapid eye movement Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 201000002859 sleep apnea Diseases 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000024188 startle response Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KYNSFYRQDOSMBH-KRWDZBQOSA-N (2s)-1-(4-methylphenyl)sulfonyl-n-phenylpyrrolidine-2-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=CC=CC=2)CCC1 KYNSFYRQDOSMBH-KRWDZBQOSA-N 0.000 description 2
- BPZROJBFWUPMAB-LURJTMIESA-N (2s)-1-(5-bromothiophen-2-yl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=C(Br)S1 BPZROJBFWUPMAB-LURJTMIESA-N 0.000 description 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- KCHLDNLIJVSRPK-UHFFFAOYSA-N 3-methylsulfanylaniline Chemical compound CSC1=CC=CC(N)=C1 KCHLDNLIJVSRPK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 0 CC(C)(C)OC(N(CCC1)[C@@]1C(N*)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@]1C(N*)=O)=O 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 208000001613 Gambling Diseases 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 206010027944 Mood disorder due to a general medical condition Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000011962 Substance-induced mood disease Diseases 0.000 description 2
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006389 acute stress response Effects 0.000 description 2
- 201000007034 advanced sleep phase syndrome Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 235000021407 appetite control Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 235000019788 craving Nutrition 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 2
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001073 episodic memory Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 238000012632 fluorescent imaging Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 206010020765 hypersomnia Diseases 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000005056 memory consolidation Effects 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
- 230000003818 metabolic dysfunction Effects 0.000 description 2
- HQEIPVHJHZTMDP-JEDNCBNOSA-N methyl (2s)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1CCCN1 HQEIPVHJHZTMDP-JEDNCBNOSA-N 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 2
- 230000000446 orexinergic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 208000023515 periodic limb movement disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LWZATQDWEXAGQR-LLVKDONJSA-N (2r)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(O)=O)CCC1 LWZATQDWEXAGQR-LLVKDONJSA-N 0.000 description 1
- IZEZMFABUYWQOT-KRWDZBQOSA-N (2s)-1-(3,4-dichlorophenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound CSC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2)=C1 IZEZMFABUYWQOT-KRWDZBQOSA-N 0.000 description 1
- SBHJWGVUVFVDMN-JTQLQIEISA-N (2s)-1-(3,4-dichlorophenyl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 SBHJWGVUVFVDMN-JTQLQIEISA-N 0.000 description 1
- IQSQEFWIYQXNHP-SFHVURJKSA-N (2s)-1-(3,4-dimethoxyphenyl)sulfonyl-n-(3,5-dimethylphenyl)pyrrolidine-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(C)C=C(C)C=2)CCC1 IQSQEFWIYQXNHP-SFHVURJKSA-N 0.000 description 1
- KJPMTFYILXEFKW-KRWDZBQOSA-N (2s)-1-(3,4-dimethoxyphenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(SC)C=CC=2)CCC1 KJPMTFYILXEFKW-KRWDZBQOSA-N 0.000 description 1
- AROLTOAKBYNTER-KRWDZBQOSA-N (2s)-1-(3-bromophenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound CSC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=C(Br)C=CC=2)=C1 AROLTOAKBYNTER-KRWDZBQOSA-N 0.000 description 1
- ABXMPGQGXIVRSU-SFHVURJKSA-N (2s)-1-(3-chloro-4-methylphenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound CSC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=C(Cl)C(C)=CC=2)=C1 ABXMPGQGXIVRSU-SFHVURJKSA-N 0.000 description 1
- NPUOZBQFFCKVBZ-KRWDZBQOSA-N (2s)-1-(3-chlorophenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound CSC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=C(Cl)C=CC=2)=C1 NPUOZBQFFCKVBZ-KRWDZBQOSA-N 0.000 description 1
- MENYSNIOINZHOK-SFHVURJKSA-N (2s)-1-(3-methoxyphenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound COC1=CC=CC(S(=O)(=O)N2[C@@H](CCC2)C(=O)NC=2C=C(SC)C=CC=2)=C1 MENYSNIOINZHOK-SFHVURJKSA-N 0.000 description 1
- ABBWCZLJPRXWMF-KRWDZBQOSA-N (2s)-1-(4-bromophenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound CSC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ABBWCZLJPRXWMF-KRWDZBQOSA-N 0.000 description 1
- ORZCOQODYMJAIP-JTQLQIEISA-N (2s)-1-(4-bromophenyl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=C(Br)C=C1 ORZCOQODYMJAIP-JTQLQIEISA-N 0.000 description 1
- GSDUZVVKIQFVTB-INIZCTEOSA-N (2s)-1-(4-chlorophenyl)sulfonyl-n-(3,5-dichlorophenyl)pyrrolidine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(Cl)C=C(Cl)C=2)CCC1 GSDUZVVKIQFVTB-INIZCTEOSA-N 0.000 description 1
- XYVSDRGXVAWXEE-SFHVURJKSA-N (2s)-1-(4-chlorophenyl)sulfonyl-n-(3,5-dimethylphenyl)pyrrolidine-2-carboxamide Chemical compound CC1=CC(C)=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=CC(Cl)=CC=2)=C1 XYVSDRGXVAWXEE-SFHVURJKSA-N 0.000 description 1
- AANHDAUXXNPJHE-KRWDZBQOSA-N (2s)-1-(4-chlorophenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound CSC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=CC(Cl)=CC=2)=C1 AANHDAUXXNPJHE-KRWDZBQOSA-N 0.000 description 1
- JXMXHRZHMZMBDK-JTQLQIEISA-N (2s)-1-(4-chlorophenyl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=C(Cl)C=C1 JXMXHRZHMZMBDK-JTQLQIEISA-N 0.000 description 1
- DIUDVHGBTFDFCN-SFHVURJKSA-N (2s)-1-(4-methoxyphenyl)sulfonyl-n-(3-methylsulfanylphenyl)pyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(SC)C=CC=2)CCC1 DIUDVHGBTFDFCN-SFHVURJKSA-N 0.000 description 1
- YSBGRVXJEMSEQY-DEOSSOPVSA-N (2s)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-n-(2-phenylphenyl)pyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1CCCN1C(=O)CSC=1N(C2=CC=CC=C2N=1)C)NC1=CC=CC=C1C1=CC=CC=C1 YSBGRVXJEMSEQY-DEOSSOPVSA-N 0.000 description 1
- FONPGCAGFNPFCY-SFHVURJKSA-N (2s)-1-[4-chloro-3-(trifluoromethyl)phenyl]sulfonyl-n-(3,5-dimethylphenyl)pyrrolidine-2-carboxamide Chemical compound CC1=CC(C)=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C1 FONPGCAGFNPFCY-SFHVURJKSA-N 0.000 description 1
- SOZVMQYBZHHSQC-FQEVSTJZSA-N (2s)-n-(2,3-dihydro-1h-inden-5-yl)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C3CCCC3=CC=2)CCC1 SOZVMQYBZHHSQC-FQEVSTJZSA-N 0.000 description 1
- PQTLJUDQIGCUJE-LBPRGKRZSA-N (2s)-n-(3,5-dimethylphenyl)pyrrolidine-2-carboxamide Chemical compound CC1=CC(C)=CC(NC(=O)[C@H]2NCCC2)=C1 PQTLJUDQIGCUJE-LBPRGKRZSA-N 0.000 description 1
- ZUXORUOIXXGXQQ-YDALLXLXSA-N (2s)-n-(3,5-dimethylphenyl)pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC1=CC(C)=CC(NC(=O)[C@H]2NCCC2)=C1 ZUXORUOIXXGXQQ-YDALLXLXSA-N 0.000 description 1
- KQHJEETVAWQSRQ-KRWDZBQOSA-N (2s)-n-(3-bromophenyl)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(Br)C=CC=2)CCC1 KQHJEETVAWQSRQ-KRWDZBQOSA-N 0.000 description 1
- OIUHGQQIRSMLFE-KRWDZBQOSA-N (2s)-n-(3-chlorophenyl)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(Cl)C=CC=2)CCC1 OIUHGQQIRSMLFE-KRWDZBQOSA-N 0.000 description 1
- QIVKKCHLBIIWOR-IBGZPJMESA-N (2s)-n-(3-ethylphenyl)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound CCC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 QIVKKCHLBIIWOR-IBGZPJMESA-N 0.000 description 1
- WOQNVEBUHZAZDX-KRWDZBQOSA-N (2s)-n-(3-methylsulfanylphenyl)-1-[4-(trifluoromethyl)phenyl]sulfonylpyrrolidine-2-carboxamide Chemical compound CSC1=CC=CC(NC(=O)[C@H]2N(CCC2)S(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 WOQNVEBUHZAZDX-KRWDZBQOSA-N 0.000 description 1
- NRXYBKZDRCXDOD-JTQLQIEISA-N (2s)-n-phenylpyrrolidine-2-carboxamide Chemical class O=C([C@H]1NCCC1)NC1=CC=CC=C1 NRXYBKZDRCXDOD-JTQLQIEISA-N 0.000 description 1
- FECMKDZDRSAXDZ-UHFFFAOYSA-N 1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C(C(N)=O)CCC1 FECMKDZDRSAXDZ-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- WGYBIEOLAFYDEC-UHFFFAOYSA-N 5-bromothiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)S1 WGYBIEOLAFYDEC-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000021500 Breathing-related sleep disease Diseases 0.000 description 1
- ZZSGAAGELKETSE-ZETCQYMHSA-N COC([C@H](CCC1)N1S(c([s]1)ccc1Br)(=O)=O)=O Chemical compound COC([C@H](CCC1)N1S(c([s]1)ccc1Br)(=O)=O)=O ZZSGAAGELKETSE-ZETCQYMHSA-N 0.000 description 1
- BLWYXBNNBYXPPL-YFKPBYRVSA-N COC([C@H]1NCCC1)=O Chemical compound COC([C@H]1NCCC1)=O BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
- GGCRLIFVACLEJF-ZDUSSCGKSA-N CSc1cccc(NC([C@H](CCC2)N2S(c([s]2)ccc2Br)(=O)=O)=O)c1 Chemical compound CSc1cccc(NC([C@H](CCC2)N2S(c([s]2)ccc2Br)(=O)=O)=O)c1 GGCRLIFVACLEJF-ZDUSSCGKSA-N 0.000 description 1
- GRFMWCKVJOLAML-UHFFFAOYSA-N C[BrH]c([s]1)ccc1S(Cl)(=O)=O Chemical compound C[BrH]c([s]1)ccc1S(Cl)(=O)=O GRFMWCKVJOLAML-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010068631 Childhood depression Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013980 Dyssomnias Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000010235 Food Addiction Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 101500025902 Homo sapiens Orexin-A Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 201000001916 Hypochondriasis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000015814 Intrinsic Sleep disease Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- 208000022249 Sleep-Wake Transition disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 230000001814 effect on stress Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 238000000322 laser mass spectrometry Methods 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940068938 morphine injection Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008452 non REM sleep Effects 0.000 description 1
- 230000021363 nonassociative learning Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229940125636 orexin 1 receptor antagonist Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- LPPOVVJDAVMOET-UHFFFAOYSA-N pyrrolidine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCCC1 LPPOVVJDAVMOET-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2010053799 | 2010-08-24 | ||
| PCT/IB2011/053693 WO2012025877A1 (en) | 2010-08-24 | 2011-08-23 | Proline sulfonamide derivatives as orexin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2769607T3 true ES2769607T3 (es) | 2020-06-26 |
Family
ID=44658790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11758563T Active ES2769607T3 (es) | 2010-08-24 | 2011-08-23 | Derivados de prolina sulfonamida como antagonistas del receptor de orexina |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8895606B2 (enExample) |
| EP (1) | EP2608787B1 (enExample) |
| JP (1) | JP5744203B2 (enExample) |
| KR (1) | KR101802726B1 (enExample) |
| CN (1) | CN103079563B (enExample) |
| CA (1) | CA2807000C (enExample) |
| ES (1) | ES2769607T3 (enExample) |
| TW (1) | TW201209037A (enExample) |
| WO (1) | WO2012025877A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2608787B1 (en) | 2010-08-24 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| DK2855453T3 (en) | 2012-06-04 | 2017-02-06 | Actelion Pharmaceuticals Ltd | Benzimidazol-proline derivatives |
| CN105793257B (zh) | 2013-12-03 | 2018-11-13 | 爱杜西亚药品有限公司 | 苯并咪唑环化合物的晶形及其用途 |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| WO2021207678A1 (en) * | 2020-04-09 | 2021-10-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Kappa opioid receptor antagonists for treating pain-related sleep disorders |
| EP4356909A1 (en) * | 2022-10-17 | 2024-04-24 | Selabtec Sciences, SLU | 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5822111B2 (ja) | 1977-10-29 | 1983-05-06 | 協和醗酵工業株式会社 | 柑橘類果実の改質剤 |
| JPS5581857A (en) | 1978-12-15 | 1980-06-20 | Kyowa Hakko Kogyo Co Ltd | Modifier of citrus fruit |
| US6291453B1 (en) | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| NZ507760A (en) | 1998-03-26 | 2002-10-25 | Japan Tobacco Inc | Amide derivatives and nociceptin antagonists |
| DE10035144A1 (de) | 2000-07-19 | 2002-01-31 | Merck Patent Gmbh | Cyclische Aminosäurederivate |
| GB0225938D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| WO2004073634A2 (en) | 2003-02-20 | 2004-09-02 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| US7288538B2 (en) | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
| EP1697337A2 (en) | 2003-12-22 | 2006-09-06 | Astellas Pharma Inc. | Ornithine derivatives as prostaglandin-e2-agonists or antagonists |
| RU2378257C2 (ru) | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| US8143288B2 (en) * | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7998959B2 (en) | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| EA015256B1 (ru) | 2006-03-15 | 2011-06-30 | Актелион Фармасьютикалз Лтд. | Производные тетрагидроизохинолина для повышения функции памяти |
| EP2049526A2 (en) | 2006-07-14 | 2009-04-22 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| KR101343399B1 (ko) * | 2008-01-08 | 2013-12-19 | 퍼듀 퍼머 엘피 | 통증 치료를 위한 카나비노이드 수용체에 대한 리간드로서의 프롤린 유사체 |
| CN101918361B (zh) * | 2008-02-12 | 2014-05-28 | 弗·哈夫曼-拉罗切有限公司 | 哌啶磺酰胺衍生物 |
| US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
| ES2350548B1 (es) | 2009-06-25 | 2011-09-29 | Institut Univ. De Ciència I Tecnologia, S.A. | N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica. |
| ES2351323B1 (es) | 2009-06-26 | 2011-10-05 | Institut Univ. De Ciència I Tecnologia, S.A. | Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos. |
| ES2351452B1 (es) | 2009-07-01 | 2011-10-05 | Institut Univ. De Ciència I Tecnologia, S.A. | Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica. |
| EP2608787B1 (en) | 2010-08-24 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| DK2855453T3 (en) | 2012-06-04 | 2017-02-06 | Actelion Pharmaceuticals Ltd | Benzimidazol-proline derivatives |
-
2011
- 2011-08-23 EP EP11758563.8A patent/EP2608787B1/en active Active
- 2011-08-23 CN CN201180040497.4A patent/CN103079563B/zh not_active Expired - Fee Related
- 2011-08-23 ES ES11758563T patent/ES2769607T3/es active Active
- 2011-08-23 WO PCT/IB2011/053693 patent/WO2012025877A1/en not_active Ceased
- 2011-08-23 TW TW100130171A patent/TW201209037A/zh unknown
- 2011-08-23 KR KR1020137007125A patent/KR101802726B1/ko not_active Expired - Fee Related
- 2011-08-23 CA CA2807000A patent/CA2807000C/en active Active
- 2011-08-23 US US13/818,647 patent/US8895606B2/en active Active
- 2011-08-23 JP JP2013525400A patent/JP5744203B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-31 US US14/530,532 patent/US9000029B2/en active Active
-
2015
- 2015-03-05 US US14/639,934 patent/US9211279B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2807000A1 (en) | 2012-03-01 |
| US9211279B2 (en) | 2015-12-15 |
| EP2608787A1 (en) | 2013-07-03 |
| CN103079563A (zh) | 2013-05-01 |
| US8895606B2 (en) | 2014-11-25 |
| JP5744203B2 (ja) | 2015-07-08 |
| WO2012025877A1 (en) | 2012-03-01 |
| US20150057328A1 (en) | 2015-02-26 |
| TW201209037A (en) | 2012-03-01 |
| KR101802726B1 (ko) | 2017-11-29 |
| CA2807000C (en) | 2018-12-04 |
| US20150246021A1 (en) | 2015-09-03 |
| KR20130110160A (ko) | 2013-10-08 |
| EP2608787B1 (en) | 2019-11-20 |
| CN103079563B (zh) | 2015-07-08 |
| US20130150424A1 (en) | 2013-06-13 |
| JP2013538206A (ja) | 2013-10-10 |
| US9000029B2 (en) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9211279B2 (en) | Proline sulfonamide derivatives as orexin receptor antagonists | |
| JP2026053405A (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 | |
| TWI636982B (zh) | 結晶鹽形式 | |
| CN102341380A (zh) | 布美他尼、呋塞米、吡咯他尼、佐塞米和托拉塞米类似物、组合物和使用方法 | |
| CN105793257B (zh) | 苯并咪唑环化合物的晶形及其用途 | |
| CA3210270A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| BR112019014235A2 (pt) | Inibidores bicíclicos de histona desacetilase | |
| AU2014358766A1 (en) | Use of benzimidazole-proline derivatives | |
| TW202340145A (zh) | 氘化有機化合物及其用途 | |
| TW200825067A (en) | CB1 compounds | |
| WO2020007977A1 (en) | 7-trifluoromethyl-[1,4]diazepan derivatives | |
| WO2020007964A1 (en) | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives | |
| WO2020099511A1 (en) | Benzimidazole-2-methyl-morpholine derivatives | |
| HK40106138A (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| BR122024002267A2 (pt) | Derivados de psilocina como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc | |
| BR112016012625B1 (pt) | Forma cristalina de cloridrato ou hidrocloreto do composto (s)-(2-(6- cloro-7-metil-1 h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3- triazol-2-il)fenil)metanona, composição farmacêutica, e, uso da forma cristalina de hidrocloreto de (s)-(2-(6-cloro-7- metil-1h-benzo[d]imidazol-2-il)-2- metilpirrolidin-1-il)(5-metoxi-2-(2h-1 ,2,3-triazol-2-il)fenil)metanona | |
| BR112016012628B1 (pt) | Forma cristalina de hemi-hidrato do composto (s)-(2-(6-cloro-7-metil- 1h-benzo[d]imidazol-2-il)-2- metilpirrolidin-1-il)(5-metóxi-2-(2h-1,2,3-triazol-2-il) fenil)metanona, seu uso como antagonistas dos receptores da orexina, e, composição farmacêutica | |
| BR112016004412B1 (pt) | Compostos de 1,2,4-triazolo[4,3-a]piridina como moduladores alostéricos positivos de recetores mglur2, composição farmacêutica e produto que os compreende |